2022 World Conference on Lung Cancer (Posters)-P1.15-08. Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

P1.15-08. Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

IMU-201 (PD1-Vaxx) is a B-cell immunotherapy being developed as a monotherapy or in combination with atezolizumab for the treatment of non-small cell lung cancer (NSCLC). The therapy aims to stimulate polyclonal antibodies against PD-1, potentially inducing memory B- and T-cell responses and reducing immune evasion and suppression. Preliminary data from a Phase 1 study showed that IMU-201 was generally safe and well tolerated, with most adverse events reported as low-grade and manageable. Antibodies to IMU-201 were generated in patients receiving the therapy, with a dose-dependent increase in antibody production observed. Furthermore, the study showed an anti-tumor effect, with one patient achieving a complete response and others achieving stable disease or partial response. These findings support further evaluation of IMU-201 in NSCLC. The ongoing study, called IMPRINTER, is evaluating the safety, tolerability, and efficacy of IMU-201 as monotherapy or in combination with atezolizumab. Eligible patients must have previously received an immune checkpoint inhibitor and experienced disease progression. The study aims to identify the optimal biological dose of IMU-201 and evaluate its immunogenicity and cellular response. Safety data from the study showed that IMU-201 was generally well tolerated, with no dose-limiting toxicities observed. However, two cases of immune-mediated pneumonitis were reported, leading to the withdrawal of the patients from the study. The study design includes regular tumor evaluations according to RECIST 1.1 criteria. The next steps are to evaluate the immune-mediated response to IMU-201 and to combine it with atezolizumab, a checkpoint inhibitor. Overall, these findings suggest that IMU-201 shows promise as a potential immunotherapy for NSCLC, and further research is warranted.

Asset Subtitle

Michael Boyer, Australia

Meta Tag

Speaker Michael Boyer, Australia

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

IMU-201

PD1-Vaxx

B-cell immunotherapy

non-small cell lung cancer

NSCLC

polyclonal antibodies

immune evasion

immune suppression

Phase 1 study

complete response